FIELD: biotechnology.
SUBSTANCE: disclosed are anti-AXL antibodies and pharmaceutical compositions containing them, as well as methods of using them in treating cancer.
EFFECT: invention can find further application in anticancer therapy.
24 cl, 10 dwg, 7 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
ANTI-CD137 ANTIGEN-BINDING MOLECULES AND USE THEREOF | 2019 |
|
RU2829536C2 |
ANTIGEN-BINDING POLYPEPTIDE BINDING TO CD47, AND USE THEREOF | 2021 |
|
RU2833294C2 |
BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
Authors
Dates
2025-04-02—Published
2021-02-26—Filed